Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hansa Biopharma AB (HNSA) Fair Value & Analysis

Healthcare · SE · Market cap 3.1B SEK

Pricekr 34.00
Fair Valuekr 7.80
Upside-77.1%
Quality95/100
Evidence: Low Range kr 5.85 – kr 9.75

Fair value as of: Jun 23, 2026

Analysis

Hansa Biopharma AB (HNSA) currently trades at kr 34.00, while our model-based Fair Value estimate is kr 7.80 — implying the stock looks roughly 77.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD) and research and development collaboration agreement with Genethon to evaluate the safety and effica…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Hansa Biopharma AB (HNSA) undervalued?
As of Jun 23, 2026, our model estimates a fair value of kr 7.80 versus a price of kr 34.00 — about −77% (overvalued). Model-based estimate, not financial advice.
What is the fair value of HNSA?
Our 21-model fair value for Hansa Biopharma AB is kr 7.80 (as of Jun 23, 2026), built from audited fundamentals. The current price is kr 34.00.
What is the quality score of HNSA?
Hansa Biopharma AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.